Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

The design of novel inhibitors to target BACE1 with reduced cytotoxicity effects is a promising approach to treat Alzheimer's disease (AD). Multiple clinical drugs and antibodies such as AZD3293 and Solanezumab are being tested to investigate their therapeutical potential against AD. The current study explores the binding pattern of AZD3293 and Solanezumab against their target proteins such as β-secretase (BACE1) and mid-region amyloid-beta (Aβ) (PDBIDs: 2ZHV & 4XXD), respectively using molecular docking and dynamic simulation (MD) approaches. The molecular docking results show that AZD3293 binds within the active region of BACE1 by forming hydrogen bonds against Asp32 and Lys107 with distances 2.95 and 2.68 Å, respectively. However, the heavy chain of Solanezumab interacts with Lys16 and Asp23 of amyloid beta having bond length 2.82, 2.78, and 3.00 Å, respectively. The dynamic cross correlations and normal mode analyses show that BACE1 depicted good residual correlated motions and fluctuations, as compared to Solanezumab. Using MD, the Root Mean Square Deviation and Fluctuation (RMSD/F) graphs show that AZD3293 residual fluctuations and RMSD value (0.2 nm) was much better compared to Solanezumab (0.7 nm). Moreover, the radius of gyration (Rg) results also depicts the significance of AZD3293 docked complex compared to Solanezumab through residual compactness. Our comparative results show that AZD3293 is a better therapeutic agent for treating AD than Solanezumab.

[1]  Qamar Abbas,et al.  Pharmacoinformatics exploration of polyphenol oxidases leading to novel inhibitors by virtual screening and molecular dynamic simulation study , 2017, Comput. Biol. Chem..

[2]  M. Ivanova,et al.  Reduced Lipid Bilayer Thickness Regulates the Aggregation and Cytotoxicity of Amyloid-β* , 2017, The Journal of Biological Chemistry.

[3]  S. Haeberlein,et al.  AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[4]  M. Rosales-Hernández,et al.  Asp32 and Asp228 determine the selective inhibition of BACE1 as shown by docking and molecular dynamics simulations. , 2016, European journal of medicinal chemistry.

[5]  Xin-Qiu Yao,et al.  Online interactive analysis of protein structure ensembles with Bio3D-web , 2016, Bioinform..

[6]  Mubashir Hassan,et al.  Exploration of Novel Human Tyrosinase Inhibitors by Molecular Modeling, Docking and Simulation Studies , 2016, Interdisciplinary Sciences: Computational Life Sciences.

[7]  Xin-Qiu Yao,et al.  Rapid Characterization of Allosteric Networks with Ensemble Normal Mode Analysis. , 2016, The journal of physical chemistry. B.

[8]  H. Ågren,et al.  A High Affinity Red Fluorescence and Colorimetric Probe for Amyloid β Aggregates , 2016, Scientific Reports.

[9]  Dan Li,et al.  The application of in silico drug-likeness predictions in pharmaceutical research. , 2015, Advanced drug delivery reviews.

[10]  M. Parker,et al.  Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies , 2015, Scientific Reports.

[11]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[12]  R. Vassar.  BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[13]  Patrick Walsh,et al.  Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease. , 2014, Chemical Society reviews.

[14]  L. Maron,et al.  Aqueous microsolvation of CdCl₂: density functional theory and Born-Oppenheimer molecular dynamics studies. , 2014, The Journal of chemical physics.

[15]  S. Haeberlein,et al.  MONITORING THE SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA (SAPPA) AND BETA (SAPPB) FRAGMENTS IN PLASMA AND CSF FROM HEALTHY INDIVIDUALS TREATED WITH BACE INHIBITOR AZD3293 IN A MULTIPLE ASCENDING DOSE STUDY: PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATE , 2014, Alzheimer's & Dementia.

[16]  Calvin Yu-Chian Chen,et al.  In Silico Design of BACE1 Inhibitor for Alzheimer's Disease by Traditional Chinese Medicine , 2014, BioMed research international.

[17]  David B. Ascher,et al.  Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? , 2014, Acta Neuropathologica.

[18]  Daniel Oehlrich,et al.  The evolution of amidine-based brain penetrant BACE1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[19]  L. Ereshefsky,et al.  AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration , 2014, Neurobiology of Aging.

[20]  Arun K. Ghosh,et al.  The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors. , 2013, Current topics in medicinal chemistry.

[21]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[22]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[23]  Arthur J. Olson,et al.  Automated Docking with Protein Flexibility in the Design of Femtomolar "Click Chemistry" Inhibitors of Acetylcholinesterase , 2013, J. Chem. Inf. Model..

[24]  E. Siemers,et al.  Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[25]  Arup K. Ghose,et al.  Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery , 2011, ACS chemical neuroscience.

[26]  Pradeep Kota,et al.  Automated minimization of steric clashes in protein structures , 2011, Proteins.

[27]  Abdul Samad,et al.  Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives. , 2010, European journal of medicinal chemistry.

[28]  Christian Holm,et al.  Optimizing working parameters of the smooth particle mesh Ewald algorithm in terms of accuracy and efficiency. , 2010, The Journal of chemical physics.

[29]  Vincent B. Chen,et al.  MolProbity: all-atom structure validation for macromolecular crystallography , 2009, Acta crystallographica. Section D, Biological crystallography.

[30]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[31]  Eric Jakobsson,et al.  An improved united atom force field for simulation of mixed lipid bilayers. , 2009, The journal of physical chemistry. B.

[32]  Peter J. Crouch,et al.  The role of metals in modulating metalloprotease activity in the AD brain , 2008, European Biophysics Journal.

[33]  Rameshwar U. Kadam,et al.  Recent trends in drug-likeness prediction: A comprehensive review of In silico methods , 2007 .

[34]  Philip C Biggin,et al.  Molecular dynamics studies of AChBP with nicotine and carbamylcholine: the role of water in the binding pocket. , 2007, Protein engineering, design & selection : PEDS.

[35]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[36]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[37]  David S. Wishart,et al.  VADAR: a web server for quantitative evaluation of protein structure quality , 2003, Nucleic Acids Res..

[38]  Ian W. Davis,et al.  Structure validation by Cα geometry: ϕ,ψ and Cβ deviation , 2003, Proteins.

[39]  Lin Hong,et al.  Crystal Structure of Memapsin 2 (β-Secretase) in Complex with an Inhibitor OM00-3† , 2002 .

[40]  A. Beresford,et al.  The emerging importance of predictive ADME simulation in drug discovery. , 2002, Drug discovery today.

[41]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[43]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[44]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[45]  A. Moustafa,et al.  Finding Novel Anti-carcinomas Compounds by Targeting SFRP4 Through Molecular Modeling, Docking and Dynamic Simulation Studies. , 2018, Current computer-aided drug design.

[46]  Prerana B. Jadhav,et al.  CONCEPT OF DRUG LIKENESS IN PHARMACEUTICAL RESEARCH , 2015 .

[47]  Arun K. Ghosh,et al.  Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. , 2002, Biochemistry.

[48]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.